Polypid Ltd's Comment on Sales, Marketing and Customers
The company serves customers who bill federal healthcare programs, including physicians who may receive consulting fees and other benefits related to product prescriptions. Its markets include federal healthcare programs such as Medicare and Medicaid, as well as private third-party payors. These healthcare benefit programs are subject to various federal and state laws regulating fraud, abuse, and payment practices within the healthcare industry.
PolyPid Poised to Revolutionize Post-Surgical Care: A Closer Look at the Upcoming KOL Event and D-PLEX Phase 3 Trial Progress By Author s Name for CSIMarket.com In the fast-paced arena of biopharmaceutical innovation, few companies are drawing as much attention as PolyPid Ltd. (Nasdaq: PYPD). This late-stage biopharma company, headquartered in Petach Tikva, Israel, has made significant strides in addressing the enormous issue of surgical site infections (SSIs), which remain a major challenge in the medical field. As the anticipation builds, PolyPid has announced it will host a virtual Key Opinion Leader (KOL) event on June 17, 2024, at 10:00 AM ET. This much-anticipated event will shine a spotlight on the...
Surgical site infections (SSIs) are a serious concern, particularly in abdominal colorectal procedures, as they can lead to increased morbidity, prolonged hospital stays, and significant healthcare costs. PolyPid, a leading pharmaceutical company, has recently announced the enrollment of the 200th patient in their ongoing SHIELD II Phase 3 trial evaluating D-PLEX, a novel drug delivery system. This article aims to provide a comprehensive review of the current understanding of abdominal colorectal SSIs, discuss the potential of D-PLEX, and shed light on the significance of the ongoing SHIELD II trial.Understanding Abdominal Colorectal Surgical Site Infections:Abdominal colorectal SSIs are a common occurrence,...
Polypid Ltd’s Comment on Sales, Marketing and Customers
The company serves customers who bill federal healthcare programs, including physicians who may receive consulting fees and other benefits related to product prescriptions. Its markets include federal healthcare programs such as Medicare and Medicaid, as well as private third-party payors. These healthcare benefit programs are subject to various federal and state laws regulating fraud, abuse, and payment practices within the healthcare industry.
Sources:
Polypid Ltd’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Polypid Ltd’s corporate clients.
For your research, we’ve provided 9 tables on Polypid Ltd corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
